Replies to post #803 on Verastem (VSTM)

[axelvento]

$7.46 Updated safety and efficacy results from the RAMP 205 trial of avutometinib and defactinib in combination with current standard of care in first-line metastatic pancreatic cancer to be announced at the 2025 ASCO Annual Meeting

The ASCO 2025 Annual Meeting will be held from May 30 to June 3, 2025

Ended Q1 2025 with $117.6 million in cash and cash equivalents; pro-forma $192.6 million including the equity issuance in the private placement in April 2025

https://www.biospace.com/press-releases/verastem-oncology-reports-first-quarter-2025-financial-results-and-highlights-recent-business-updates